Tirzepatide

Tirzepatide
	Structure of tirzepatide
Trade names	Zepbound, Mounjaro
Drug class	Dual GIP and GLP-1 receptor agonist, incretin therapy
Routes of administration	Subcutaneous injection
Uses	Chronic weight management, obesity, overweight with weight-related conditions, type 2 diabetes, obstructive sleep apnea in adults with obesity ;
Dosing frequency	Once weekly ; ; ; ;
Manufacturer	Eli Lilly and Company ;
Related drugs	Semaglutide, Wegovy, Ozempic, Liraglutide, Saxenda, GLP-1 receptor agonist, medical weight loss

Tirzepatide for weight loss, Zepbound, Mounjaro, type 2 diabetes, and obstructive sleep apnea

W8MD Weight Loss, Sleep and MedSpa provides physician-supervised medical weight loss, GLP-1 weight loss, sleep apnea care, and long-term weight maintenance support.

Tirzepatide has produced substantial weight loss in clinical trials when combined with a reduced-calorie diet and increased physical activity.

Zepbound is the weight loss and obstructive sleep apnea brand of tirzepatide.

Safe use of tirzepatide requires medical screening, dose titration, side-effect monitoring, nutrition support, and long-term follow-up.

Tirzepatide is a once-weekly injectable prescription incretin therapy used for weight loss, chronic weight management, type 2 diabetes, and moderate-to-severe obstructive sleep apnea in adults with obesity. Tirzepatide is the active ingredient in two major brand-name medications: Zepbound, which is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, and Mounjaro, which is FDA-approved to improve blood glucose control in adults with type 2 diabetes.FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.MOUNJARO prescribing information(link). U.S. Food and Drug Administration.

Although tirzepatide is often discussed with GLP-1 receptor agonist medications, it is more specifically a dual GIP receptor and GLP-1 receptor agonist. This dual incretin action helps regulate appetite, satiety, insulin secretion, glucagon, gastric emptying, blood glucose, and body weight. Tirzepatide has become one of the most important advances in obesity medicine because it addresses the biology of hunger, fullness, and metabolic disease rather than relying only on willpower or short-term dieting.

W8MD Weight Loss, Sleep and MedSpa Centers in Brooklyn, New York City, and Philadelphia, Pennsylvania, can help eligible patients determine whether tirzepatide, Zepbound, or Mounjaro may be appropriate as part of a physician-supervised medical weight loss, sleep apnea, type 2 diabetes, insulin resistance, and long-term weight maintenance program.

Overview

Tirzepatide is a major development in medical weight loss and diabetes care. It was originally approved in the United States as Mounjaro for type 2 diabetes and later approved as Zepbound for chronic weight management. In December 2024, Zepbound became the first FDA-approved medication for moderate-to-severe obstructive sleep apnea in adults with obesity, to be used with a reduced-calorie diet and increased physical activity.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.

Tirzepatide may be relevant for patients with:

Tirzepatide brand names

Tirzepatide as Zepbound

Zepbound is the brand name for tirzepatide used for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is intended to be used with a reduced-calorie diet and increased physical activity.ZEPBOUND prescribing information(link). U.S. Food and Drug Administration.

Tirzepatide as Mounjaro

Mounjaro is the brand name for tirzepatide used to improve glycemic control in adults with type 2 diabetes. Mounjaro can also cause significant weight loss, but its FDA indication is for type 2 diabetes rather than chronic weight management.

How Tirzepatide works

Tirzepatide works by activating two incretin hormone pathways:

Glucose-dependent insulinotropic polypeptide receptor
GIP receptor
Glucagon-like peptide-1 receptor
GLP-1 receptor

These pathways influence multiple aspects of metabolism, including:

Tirzepatide can help patients eat less by reducing hunger and increasing fullness. It can also improve blood sugar control by increasing glucose-dependent insulin secretion and reducing inappropriate glucagon activity.

Tirzepatide for weight loss

Tirzepatide has demonstrated substantial weight-loss effects in people with obesity or overweight. In the SURMOUNT-1 trial, adults without diabetes but with obesity or overweight and at least one weight-related complication received once-weekly tirzepatide or placebo for 72 weeks. Participants receiving tirzepatide had much greater average weight loss than those receiving placebo."Tirzepatide Once Weekly for the Treatment of Obesity".New England Journal of Medicine.2022;387(3)

205-216.doi:10.1056/NEJMoa2206038.PMID:35658024.

In the FDA approval summary for chronic weight management, the highest approved Zepbound dose was associated with an average weight reduction of about 18% in the larger trial, compared with placebo.FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.

Potential weight-loss benefits include:

Reduced hunger
Improved fullness
Reduced calorie intake
Reduced waist circumference
Improved insulin resistance
Improved blood glucose
Improved metabolic syndrome
Improved fatty liver disease risk factors
Reduced sleep apnea severity in selected patients
Improved long-term weight maintenance when continued with lifestyle care

Tirzepatide and sleep apnea

Obstructive sleep apnea is a condition in which the upper airway repeatedly collapses during sleep, causing breathing pauses, oxygen drops, snoring, fragmented sleep, and daytime fatigue. Obesity is one of the strongest risk factors for obstructive sleep apnea.

In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on two randomized, double-blind, placebo-controlled studies of adults with moderate-to-severe OSA and obesity. The studies included one group using positive airway pressure and another group unable or unwilling to use PAP. Patients received Zepbound 10 mg or 15 mg or placebo once weekly for 52 weeks.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.

The SURMOUNT-OSA trials reported that tirzepatide reduced apnea-hypopnea index, body weight, hypoxic burden, high-sensitivity C-reactive protein, and systolic blood pressure, while improving sleep-related outcomes."Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity".New England Journal of Medicine.2024;PMID:38912654.

This indication is especially relevant to W8MD Weight Loss, Sleep and MedSpa because W8MD combines medical weight loss with sleep medicine, including sleep apnea screening, home sleep testing when appropriate, CPAP, BiPAP, and PAP therapy support.

Tirzepatide and type 2 diabetes

Mounjaro is FDA-approved to improve blood glucose control in adults with type 2 diabetes. Tirzepatide improves diabetes control by acting on incretin pathways that regulate insulin and glucagon.

Potential diabetes-related benefits include:

Lower Hemoglobin A1c
Improved fasting glucose
Improved post-meal glucose
Reduced insulin resistance
Reduced appetite
Weight loss
Reduced need for some diabetes medications in selected patients
Improved cardiometabolic risk markers

In SURPASS-2, tirzepatide was superior to semaglutide 1 mg for reduction in glycated hemoglobin in adults with type 2 diabetes and also produced greater body-weight reduction."Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes".New England Journal of Medicine.2021;385(6)

503-515.doi:10.1056/NEJMoa2107519.PMID:34170647.

Tirzepatide and prediabetes prevention

Tirzepatide may help reduce progression from prediabetes to type 2 diabetes in people with obesity. In longer-term analyses, tirzepatide was associated with sustained weight loss and delayed progression to type 2 diabetes among participants with obesity and prediabetes."Tirzepatide for Obesity Treatment and Diabetes Prevention".New England Journal of Medicine.2024;doi:10.1056/NEJMoa2410819.

Tirzepatide compared with Semaglutide

Semaglutide, marketed as Wegovy for chronic weight management and Ozempic for type 2 diabetes, is another highly effective incretin-based medication. Tirzepatide and semaglutide are both useful tools in obesity medicine, but tirzepatide has shown greater average weight loss in some studies.

In the SURMOUNT-5 head-to-head trial, adults with obesity but without diabetes had greater mean weight reduction with tirzepatide than with semaglutide over 72 weeks; gastrointestinal adverse events were the most common side effects in both groups and were mostly mild to moderate during dose escalation."Tirzepatide as Compared with Semaglutide for the Treatment of Obesity".New England Journal of Medicine.2025;doi:10.1056/NEJMoa2416394.

Medication choice should be individualized based on:

Weight-loss goals
Type 2 diabetes status
Sleep apnea status
Cardiovascular disease history
Medication tolerance
Side effect history
Pregnancy plans
Insurance coverage
Medication availability
Patient preference

Tirzepatide and cardiovascular risk

Obesity increases risk for cardiovascular disease, heart attack, stroke, hypertension, dyslipidemia, sleep apnea, type 2 diabetes, and chronic inflammation. Tirzepatide improves several cardiometabolic risk factors through weight loss and metabolic improvement. However, the specific FDA cardiovascular risk reduction indication currently belongs to Wegovy for adults with established cardiovascular disease and obesity or overweight, while Zepbound has FDA indications for chronic weight management and obstructive sleep apnea in adults with obesity.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.

Tirzepatide and fatty liver disease

Fatty liver disease, now often called metabolic dysfunction-associated steatotic liver disease, is closely linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Weight loss is one of the most important treatments for fatty liver disease. Tirzepatide may help some patients by reducing body weight, visceral fat, and insulin resistance, though liver disease should be monitored by a clinician.

Tirzepatide and inflammation

Obesity is associated with chronic low-grade inflammation. In the obstructive sleep apnea trials, tirzepatide reduced high-sensitivity C-reactive protein, a marker of inflammation, along with reductions in apnea-hypopnea index and body weight."Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity".New England Journal of Medicine.2024;PMID:38912654.

Tirzepatide dosing and administration

Tirzepatide is injected once weekly under the skin. Injection sites include:

Abdomen
Thigh
Upper arm

General administration instructions include:

Inject once weekly.
Use the same day each week when possible.
Inject with or without food.
Rotate injection sites.
Do not inject into the exact same spot repeatedly.
Follow the prescribed dose escalation schedule.
Do not use two tirzepatide products together.
Do not combine with another GLP-1 receptor agonist unless specifically instructed by a qualified clinician.

Missed dose instructions

If a dose is missed, the patient should take it as soon as possible within 4 days, or 96 hours. If more than 4 days have passed, the missed dose should be skipped and the next dose should be taken on the regularly scheduled day.ZEPBOUND prescribing information(link). U.S. Food and Drug Administration.

Storage

Tirzepatide products should generally be stored in the refrigerator in the original carton to protect from light. Zepbound may be stored at room temperature up to 86°F or 30°C for up to 21 days if needed. It should not be frozen.ZEPBOUND prescribing information(link). U.S. Food and Drug Administration.

Who may be a candidate for Tirzepatide?

Candidates may include adults with:

Obesity
Body mass index of 30 kg/m² or greater
Overweight
Body mass index of 27 kg/m² or greater with weight-related conditions
Type 2 diabetes
Prediabetes
Insulin resistance
Hypertension
Dyslipidemia
Obstructive sleep apnea
Fatty liver disease
Metabolic syndrome
Polycystic ovary syndrome
Weight regain

Eligibility should be determined by a qualified healthcare provider.

Who should not use Tirzepatide?

Tirzepatide should not be used in patients with:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Serious hypersensitivity to tirzepatide
Pregnancy without physician guidance
Use of another tirzepatide-containing product
Use with another GLP-1 receptor agonist unless directed by a specialist

Important precautions

Patients should discuss the following before starting tirzepatide:

History of pancreatitis
Gallbladder disease
Severe gastrointestinal disease
Gastroparesis
Kidney disease
Diabetic retinopathy
Type 2 diabetes medications
Insulin use
Sulfonylurea use
Pregnancy plans
Breastfeeding
History of depression or self-harm
Current medications and supplements

Common side effects

Common side effects may include:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Indigestion
Heartburn
Belching
Fatigue
Injection site reactions
Hair loss
Reduced appetite

Tirzepatide is not a stimulant appetite suppressant like phentermine, so it has a different side-effect profile than older stimulant weight loss medications. The most common adverse effects are gastrointestinal and often occur during dose escalation.

Serious side effects

Serious possible side effects include:

Pancreatitis
Gallbladder disease
Severe dehydration
Kidney injury
Serious allergic reaction
Severe stomach problems
Low blood sugar when used with insulin or sulfonylureas
Vision changes in patients with diabetes
Mood changes or suicidal thoughts

Patients should seek urgent medical care for severe abdominal pain, persistent vomiting, symptoms of dehydration, difficulty breathing, swelling of the face or throat, severe allergic reaction, or symptoms of very low blood sugar.

Drug interactions

Tirzepatide slows gastric emptying and may affect absorption of certain oral medications. It can also increase the risk of hypoglycemia when used with insulin or sulfonylureas.

Medication review is important for patients taking:

Insulin
Sulfonylureas
Oral diabetes medications
Blood pressure medications
Oral contraceptives
Narrow therapeutic index medications
Supplements
Herbal products

Tirzepatide and nutrition

Tirzepatide works best as part of a structured lifestyle plan. Because appetite may decrease significantly, patients should focus on nutrition quality.

A tirzepatide nutrition plan should emphasize:

Adequate protein
Hydration
Non-starchy vegetables
Fiber
Smaller meals
Reduced added sugar
Reduced refined carbohydrates
Avoidance of greasy meals if nausea occurs
Balanced electrolytes
Meal planning
Prevention of constipation

Tirzepatide and muscle preservation

During major weight loss, patients may lose some lean body mass along with fat. To reduce unnecessary muscle loss, patients should focus on:

Protein for weight loss
Resistance training
Strength training
Adequate calories
Meal replacements when appropriate
Body composition awareness
Follow-up monitoring

Tirzepatide and long-term weight maintenance

Obesity is a chronic condition, and weight regain can occur if treatment stops or long-term lifestyle structure is lost. A long-term maintenance plan may include:

Continued medical follow-up
Weight monitoring
Waist circumference tracking
Protein goals
Meal replacement backup plan
Resistance training
Sleep apnea treatment adherence
Medication continuation or taper planning
Relapse prevention
Early restart plan for weight regain

Tirzepatide popularity

Tirzepatide became widely known because of its strong weight-loss effects and public interest in Mounjaro and Zepbound. However, popularity should not replace medical judgment. Tirzepatide is a prescription medication with important contraindications, precautions, and side effects. It should be used only under the care of a qualified healthcare provider.

Other weight loss medications

Other medications used in medical weight loss may include:

How W8MD can help with Tirzepatide

W8MD Weight Loss, Sleep and MedSpa Centers can help patients determine whether tirzepatide-based therapy is appropriate and how to use it safely as part of a comprehensive medical plan.

W8MD may help with:

Medical weight loss consultation
Body mass index assessment
Waist circumference tracking
Obesity evaluation
Overweight evaluation
Type 2 diabetes risk assessment
Prediabetes screening
Insulin resistance evaluation
Sleep apnea screening
Home sleep test when appropriate
CPAP and PAP therapy support
Tirzepatide treatment planning
Zepbound evaluation
Mounjaro evaluation for diabetes
Prior authorization support when appropriate
Semaglutide comparison when appropriate
Meal replacements
Low-carbohydrate diet guidance
Protein planning
Resistance training guidance
Side effect monitoring
Long-term weight maintenance

Why W8MD is a strong choice

W8MD is not simply an injection clinic. W8MD combines obesity medicine, medical weight loss, sleep medicine, nutrition counseling, medication management, and long-term maintenance planning.

Reasons patients may choose W8MD include:

Physician-supervised care
Experience with medical weight loss since 2011
Focus on both weight loss and maintenance
GLP-1 and incretin medication knowledge
Sleep apnea testing and treatment
Nutrition and meal replacement support
Brooklyn and Philadelphia locations
Regional access for patients in New York, New Jersey, Pennsylvania, Delaware, Connecticut, and nearby areas
Telemedicine when appropriate
Individualized plans rather than one-size-fits-all programs

W8MD and sleep apnea care

Because Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, W8MD’s combined weight loss and sleep medicine model is especially relevant.

W8MD can help patients with sleep apnea by offering:

Sleep apnea screening
Home sleep test
Weight loss treatment
Zepbound evaluation when appropriate
CPAP support
PAP therapy education
Long-term follow-up
Coordination with primary care and specialists

Frequently asked questions

Is Tirzepatide the same as Zepbound?

Zepbound is a brand name for tirzepatide used for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Is Tirzepatide the same as Mounjaro?

Mounjaro is also a brand name for tirzepatide, but it is used for improving blood sugar control in adults with type 2 diabetes.

Is Tirzepatide still investigational?

No. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Some newer tirzepatide-related uses and other incretin medications remain under investigation.

Is Tirzepatide a GLP-1 medication?

Tirzepatide activates the GLP-1 receptor but is more specifically a dual GIP receptor and GLP-1 receptor agonist.

Can Tirzepatide help with sleep apnea?

Yes. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, together with reduced-calorie diet and increased physical activity.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.

How much weight can patients lose with Tirzepatide?

Weight loss varies. Clinical trials show substantial average weight loss, especially at higher doses, but individual results depend on dose, nutrition, activity, adherence, side effects, medical history, and treatment duration.

Is Tirzepatide better than Semaglutide?

In some head-to-head and comparative studies, tirzepatide produced greater average weight loss than semaglutide. However, the best medication depends on the patient’s medical history, goals, insurance, contraindications, and tolerance.

Does Tirzepatide have fewer side effects than older weight loss medications?

Tirzepatide is not a stimulant and does not work like older appetite suppressants such as phentermine. Many patients tolerate it well with gradual dose escalation, but gastrointestinal side effects are common and safety must be individualized.

Can W8MD prescribe Tirzepatide?

W8MD clinicians can evaluate whether tirzepatide-based treatment such as Zepbound or Mounjaro is medically appropriate and can help with monitoring, nutrition, sleep apnea evaluation, and weight maintenance planning.

Can Tirzepatide be used with Wegovy or Ozempic?

Zepbound should not be used with other tirzepatide-containing products or GLP-1 receptor agonist medicines unless specifically directed by a qualified clinician.ZEPBOUND prescribing information(link). U.S. Food and Drug Administration.

Can pregnant women use Tirzepatide?

Tirzepatide is not recommended during pregnancy. Patients planning pregnancy should discuss medication timing and discontinuation with their healthcare provider.

When to call a doctor

Patients using tirzepatide should call a healthcare provider for:

Severe abdominal pain
Persistent vomiting
Signs of dehydration
Symptoms of pancreatitis
Symptoms of gallbladder disease
Yellowing of the skin or eyes
Severe allergic reaction
Difficulty breathing
Severe low blood sugar
New vision changes
Mood changes
Thoughts of self-harm
Pregnancy
Severe constipation
Worsening sleep apnea symptoms

Summary

Tirzepatide is a once-weekly injectable incretin medication used as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity, and as Mounjaro for type 2 diabetes. Tirzepatide can produce substantial weight loss, improve blood glucose, reduce insulin resistance, and improve obesity-related obstructive sleep apnea when used with medical supervision, nutrition, physical activity, and long-term maintenance planning. W8MD Weight Loss, Sleep and MedSpa Centers can help eligible patients use tirzepatide safely and effectively as part of a comprehensive medical weight loss and sleep health program.

External links